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LETTERS TO THE EDITOR
Percutaneous Laser Revascularization in
Patients With Chronic Total Occlusions
As clinical investigators of the percutaneous myocardial revascu-
larization (PMR) device, we read with interest “A Prospective,
Multicenter, Randomized Trial of Percutaneous Transmyocardial
Laser Revascularization in Patients With Nonrecanalizable
Chronic Total Occlusions” (PMR-CTO trial) by Stone and
colleagues (1). Based upon the lack of available follow-up data and
objective evidence, we do not agree with their negative conclusions
regarding this study or with their generalizations regarding differ-
ent laser systems.
There was approximately 50% available follow-up data for both
primary study end points at six months: namely total exercise
duration and angina improvement. The limited six-month
follow-up data favors PMR-treated patients and may have
achieved significance with complete follow-up at 6 and 12 months.
Importantly, the review of major adverse events through six
months supports the reasonable safety of the procedure.
The discussion regarding laser technology, along with the
conclusion of the need for further study of PMR, leaves the
impression that the laser systems used in the various studies are
similar and presumes that the difference in trial outcomes is
explained by protocol design. Despite being HO:YAG systems,
the lasers used in the various studies discussed are not similar
regarding energy delivery and tissue interaction. The (DMR) laser
system used in the DIRECT study transmitted a single energy
pulse to the endocardial surface and did not advance into the
endocardium to create a channel. The DMR system was designed
for triggering an endogenous tissue response, not for channel
formation (2). The CardioGenesis PMR laser systems fiberoptics
deliver multiple energy pulses while penetrating into the myocar-
dium to create deep, non-transmural channels. Based on the
negative outcome for the DIRECT trial utilizing the DMR
system, it is clear that fiberoptic penetration into the myocardium
and significant channel formation, as with PMR, are essential to
achieving clinical benefit.
For PMR, the placebo question has been effectively addressed
by the independently conducted, randomized, double blind, true-
sham BELIEF trial, which was performed to assess the potential
of placebo as a principal mechanism for angina improvement with
the CardioGenesis Axcis PMR system. The investigators con-
cluded that the significant 12-month clinical benefit for PMR-
treated patients, compared to sham control, was not attributable to
placebo (3). During the BELIEF trial, patients, investigators, and
assessors were blinded, and cardiac medications were held con-
stant. In the PMR-CTO trial, physicians were not blinded, and
patient blinding (i.e., heavy sedation, PMR simulation, eye cov-
erage) may not have been consistently achieved. Whereas Stone
and Colleagues challenge the lack of increased exercise tolerance or
reduction in ischemia in BELIEF, the study was not designed or
intended to show a change in those measures. Studies performed
with the CardioGenesis PMR system, examining perfusion with
position emission tomography (PET), have shown significant
perfusion improvement (4,5).
Three randomized, multi-center trials [PACIFIC (6), PMR010
(7), and the independent BELIEF] encompassing nearly 650
patients have been completed with the CardioGenesis PMR
systems. All have consistently demonstrated a significant clinical
benefit favoring the PMR-treated patients in all primary end
points, with significantly improved functional capacity at 12
months. PMR is not DMR.
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REPLY
We agree with Perin et al. that a pressing clinical need exists for an
effective therapeutic approach for the large number of patients with
advanced coronary artery disease and no revascularization options
(1). However, given the potential risks and resource utilization of
laser myocardial revascularization, it is mandatory that its clinical
utility be definitively demonstrated in appropriately designed
randomized trials, especially as most studies have not shown a
reduction in inducible ischemia with this technique. In this regard,
few would question that blinding and placebo effect issues have
clouded the promising new field of laser myocardial revasculariza-
tion and have delayed the regulatory approval of this potentially
useful modality.
We attempted to address these issues with a multicenter,
randomized prospective trial of percutaneous myocardial revascu-
larization (PMR) incorporating blinding. Our trial revealed sig-
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nificant periprocedural complications associated with the laser
technique (including pericardial tamponade or effusions in 7.0% of
patients, and ventricular arrhythmias necessitating cardioversion in
5.6%), without enduring improvement in symptoms or exercise
tolerance (2). Perin and Colleagues bemoan the lack of 12-month
follow-up in our study. Unfortunately, such data was requested and
not supplied by the sponsor. Moreover, the weak trend in our study
toward less angina in PMR-treated patients at 3 months was
diminishing at 6 months, making it doubtful that 12-month
follow-up would have revealed significant symptomatic improve-
ment. Their second comment reiterates our acknowledged limita-
tion that the rate of paired exercise testing was lower than
anticipated. However, as statistically discussed in the report (2),
given the observed mean difference in exercise tolerance of only
17 s between groups, it is highly unlikely that a greater number of
patients would have altered our conclusions.
Third, Perin et al. question the fact that our study was
adequately blinded, which may have contributed to the negative
findings. This is counterintuitive; lack of blinding would have
favored the active treatment group, making the trial more positive.
Moreover, it is unclear how blinded the BELIEF study was; the
laser in the sham group was connected to a “lead box,” which likely
precluded the characteristic visual and acoustic signals when the
laser was fired. This small (only 82 randomized patients) though
well-designed study also showed no difference in exercise tolerance
between PMR and placebo groups, and incremental improvement
in angina by 1 class at 12 months in only 24% of treated patients
(n  10), which may have been due to chance given the small
sample size (3). We therefore cannot agree with their statement
that BELIEF has “effectively addressed” the placebo question,
given the results of the much larger, blinded DIRECT trial (4).
Finally, although we agree with Perin and Co-workers that the
three holmium yttrium-aluminium-garnet (YAG) laser systems
subjected to clinical trials are different, and stated so in the last
paragraph of our report (2), we strongly disagree with their
statement that “Based on the negative outcome for the DIRECT
trial utilizing the DMR system, it is clear that fiberoptic penetra-
tion into the myocardium and significant channel formation, as
with PMR, are essential to achieving clinical benefit.” Evaluating
whether the different modes of energy delivery or myocardial
penetration has anything to do with clinical efficacy would require
a comparative study between the two systems, or absent this, at
least a positive adequately sized multicenter blinded study of PMR
using the CardioGenesis system.
We suggest that rather than arguing the merits of the currently
completed trials, all of which are flawed to some degree, Perin et
al. focus on lobbying for an adequately powered, appropriately
blinded clinical trial to once and for all either prove the safety and
efficacy of PMR, or, alternatively, demonstrate its futility. Other-
wise, it is doubtful that this once promising approach will ever
become widely accepted by the clinical community.
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Stented Angioplasty or Coronary Artery
Bypass Graft Surgery for Multivessel Disease?
The recent report from the ARTS trial focuses on the effect of
completeness of revascularization on the outcome within each
cohort (1). In the previous report from the trial, on the basis of a
small difference in the cost of treatment during the first year in
favor of stented angioplasty, but in the absence of difference in the
rate of major complications and with a repeat revascularization rate
more than five times greater among the stented patients, the
investigators concluded that there is no advantage to surgery over
angioplasty in patients with multivessel disease (2). Now we learn
that when the interventional cardiologists estimated that, using
stented angioplasty, they could achieve a degree of revasculariza-
tion equal to surgical revascularization, they were, in fact, able to
provide this degree of completeness to a substantially lower
number of patients (70.5% vs. 84.1%). The significantly better
revascularization in the surgical group was accomplished without
increased incidence of stroke, myocardial infarction, or death.
Patients in this trial, who were randomized to stented angioplasty
and received incomplete revascularization (30%), could have much
better freedom from death and other major complications, reduc-
ing the need for subsequent bypass surgery from 10% to only 0.2%
to 1.1%, with only minimal effect of completeness of revascular-
ization. However, the investigators elected to emphasize the effect
of complete revascularization; the fact that even with complete
revascularization, the stented patients had a one-year event-free
survival much inferior to their surgical counterparts does not
appear, as it should, in the conclusions of their report.
Another unanswered question is what happened to the left
ventricle (LV) using an approach that resulted in the need for
repeat revascularization in every fifth patient. Were all the ischemic
episodes indicating the need for further revascularization proce-
dures free of irreversible myocardial damage? And was the subse-
quent procedure, carrying a 5% to 6% infarction rate in the index
procedure, free of damage the second time? Has LV function
remained unchanged in both groups?
The researchers conclude that the effectiveness and cost-
effectiveness of angioplasty can be further enhanced by careful
selection of patients. The cohort assigned to this study consisted of
lesser proportion of patients with totally obstructed vessels, small
or multilesion vessels, and at least two lesions in arteries 2.75
mm, leading to two different territories. Such patients are almost
ideal candidates for angioplasty. Careful selection of candidates
from among these patients will further limit the application of the
study results to the entire population of patients with multivessel
disease.
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